Metraipolis › archive › dc_22d4efd02f8b

EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 — Europe PMC PMID:41501210

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41501210
DOI
10.1038/s41388-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-11-07T00:14:13.563Z
SHA-256 of the archived text
804a5af6bd95105fccea09121bcd384d089f716fb4bc8588ba6b749d497ca92e
Stable URL of this page
https://metraipolis.com/documento/dc_22d4efd02f8b

How to cite

EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 — Europe PMC PMID:41501210 — Europe PMC (en), https://europepmc.org/article/MED/41501210 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_22d4efd02f8b (Metraipolis archive dc_22d4efd02f8b, sha256 804a5af6bd95105fccea09121bcd384d089f716fb4bc8588ba6b749d497ca92e)
BibTeX
@misc{dc22d4efd02f8b,
  title = {EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2 — Europe PMC PMID:41501210},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41501210},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_22d4efd02f8b; sha256 804a5af6bd95105fccea09121bcd384d089f716fb4bc8588ba6b749d497ca92e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41501210. Agents can read the archived copy with the MCP tool read_document.